rss
Evid Based Med 18:34-35 doi:10.1136/eb-2012-100736
  • Therapeutics
  • Randomised controlled trial

Closure of a patent foramen ovale with a device does not offer a greater benefit than medical therapy alone for the prevention of recurrent cerebrovascular events

  1. Marie-Luise Mono
  1. Department of Neurology, Inselspital, Bern, Switzerland
  1. Correspondence to: Professor Heinrich Mattle
    Department of Neurology, Freiburgstrasse, 3010 Bern, Switzerland; heinrich.mattle{at}insel.ch

Commentary on:

Context

Stroke can rarely be caused by paradoxical emboli passing from the right side of the circulatory system to the left side. Case reports have shown that the most common site of right to left shunt is the patent foramen ovale (PFO), and case control studies have shown a higher prevalence of PFO in patients with cryptogenic stroke as compared to stroke victims with a known cause or non-stroke controls. Therefore, the question arises as to whether closure of the PFO is useful in preventing recurrent stroke in patients with cryptogenic stroke and PFO.

Methods

CLOSURE is a multicentre, randomised, open-label trial of PFO closure with STARFlex, a percutaneous device, as compared with medical therapy alone in patients aged 18–60 years who presented with …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>


Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article